support

# Expert Assessment: TREM2 as a Therapeutic Target in Late-Stage Alzheimer's Disease

## Executive Summary

This hypothesis proposes a stage-specific model where TREM2 downregulation in late-stage AD represents a critical inflection point for microglial maladaptation. While TREM2 is a well-validated and druggable target with active clinical development, the specific mechanistic claim requires careful scrutiny.

---

## Target Druggability Assessment

**TREM2 is a highly druggable target.** Key attributes:

| Property | Assessment |
|----------|------------|
| **Target Class** | Cell-surface receptor (type-1 transmembrane, Ig superfamily) |
| **Genetic Validation** | Strong—